溶质载体超家族50蛋白在乳腺癌中的表达及其临床意义

Expression and clinical significance of SLC50A1 in breast carcinomas

目的:探讨溶质载体家族50蛋白成员1(SLC50A1)在乳腺癌中的表达及其临床意义。方法:选取符合入组标准的乳腺癌患者39例,使用酶联免疫吸附测定法(ELISA)对入组患者的血浆进行SLC50A1蛋白浓度检测。分别使用Kendall’s tau-b以及Mann-Whitney U检验对SLC50A1蛋白浓度与患者治疗期间的临床指标进行相关性及差异性分析,并根据log-rank检验结果进行多因素Cox回归分析。应用生物信息学技术分析TCGA数据库中乳腺癌组织及癌旁正常组织SLC50A1基因表达水平的差异。结果:乳腺癌患者血浆SLC50A1水平在早期与晚期患者组、雌激素受体阳性和阴性组、Ki67高表达与低表达组中的差异均有统计学意义(P<0.05),SLC50A1表达与CA153水平存在正相关关系(Kendall’s tau-b=0.257,P=0.004)。Cox回归分析结果显示SLC50A1表达水平是乳腺癌患者的独立预后因素(HR=0.385,P=0.03)。TCGA数据库分析结果表明,乳腺癌组织中的SLC50A1基因表达水平较癌旁正常组织升高(P<0.01)。结论:晚期乳腺癌患者血浆SLC50A1水平升高,SLC50A1表达水平是乳腺癌的独立预后因素,SLC50A1有望作为乳腺癌预后预测与治疗的靶点。

OBJECTIVE:To investigate expression of SLC50A1 and its significance in breast cancers(BC).METHODS:Plasma samples from 39 BC patients who met the inclusion criteria of this study were investigated using the enzyme-linked immunosorbent assay.The Mann-Whitney U-test and Kendall’s Tau-b were used to analyze differences and correlations between SLC50A1 protein levels and their clinical data.The multivariate Cox regression was used to investigate prognostic significance of SLC50A1 according to the results of the log-rank test.Furthermore,the TCGA database was downloaded to compared different expressions of SLC50A1 from 1109 BC and 113 adjacent normal tissues.RESULTS:Clinical data from the BC patients indicated that SLC50A1 protein expression was associated with metastasis,hormone receptor and Ki67(P<0.05).Correlation analyses of plasma SLC50A1 levels indicated a positive correlation between plasma SLC50A1level and CA153,Kendall’s Tau-b=0.257(P=0.004).Multivariate Cox regression analyses indicated that SLC50A1 was an independent prognostic factor in BC patients(HR=0.385,P=0.03).The TCGA data analyses indicated that the SLC50A1 expression levels were higher in BC than in adjacent tissues(P<0.01).CONCLUSION:Plasma SLC50A1 levels were increased in advanced BC,and SLC50A1 expression was an independent prognostic factor for BC.SLC50A1 may be useful as a target for prognosis prediction and therapy of BC.